--- title: "Weekly Recap | CRISPR Therap +11.11%, consensus target above spot" type: "News" locale: "en" url: "https://longbridge.com/en/news/296667842.md" description: "CRISPR Therap staged a sharp rebound this week, adding 11.11% to close at $59.50. That outperformed the S&P 500 (down 1.43%) by around 12.54 percentage points. The stock drifted in a $51.80–$54.57 range through Monday and Tuesday before surging on heavy volume on Wednesday (19 August) to $59.81. The rally extended to an intraweek high of $62.535 on Friday before a modest pullback, leaving a clear spike-and-consolidate pattern. Weekly amplitude hit 20." datetime: "2026-08-22T04:51:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296667842.md) - [en](https://longbridge.com/en/news/296667842.md) - [zh-HK](https://longbridge.com/zh-HK/news/296667842.md) generator: "portal-rs" --- # Weekly Recap | CRISPR Therap +11.11%, consensus target above spot ## The Week CRISPR Therap staged a sharp rebound this week, adding 11.11% to close at $59.50. That outperformed the S&P 500 (down 1.43%) by around 12.54 percentage points. The stock drifted in a $51.80–$54.57 range through Monday and Tuesday before surging on heavy volume on Wednesday (19 August) to $59.81. The rally extended to an intraweek high of $62.535 on Friday before a modest pullback, leaving a clear spike-and-consolidate pattern. Weekly amplitude hit 20.22%, and average daily volume of roughly 2.3m shares ran well above the recent median, signalling a meaningful pick-up in market engagement. ## Key Events The biopharma sector drew broad attention this week, with several industry-level narratives swirling around CRISPR Therap. Early in the week, sentiment was still digesting a sector-wide piece on the brutal commercial reality facing post-pandemic biopharma innovators, which cast a shadow over profitability timelines for smaller drug developers. The narrative shifted sharply on Thursday (20 August), when Moderna’s massive intraday rally on cancer-vaccine data lifted the mRNA and gene-editing complex. In after-hours and pre-market trading, CRISPR Therap was flagged alongside Recursion and Novavax as a trending name, stoking speculative interest. While the company did not release any material business announcements, the sector tailwind and rotation flow provided a clear sentiment boost. ## Analyst Ratings Based on the latest data, 22 brokers cover CRISPR Therap: 8 rate it buy, 5 rate it overweight and 9 rate it hold, with no underweight or sell ratings. The consensus recommendation is buy, and the consensus target price sits at $87.56—roughly 47.2% above the week’s close of $59.50. The target range is wide, from a low of $44 to a high of $291, reflecting considerable disagreement about the value of the company’s longer-dated pipeline. Within the biotechnology sector, CRISPR Therap ranks 18th out of 505 companies, placing it in the top tier of industry coverage. ## The Week Ahead A batch of US macro data arrives on Tuesday, 25 August—FHFA house price indices, the Case Shiller 20-city composite, consumer confidence and new home sales. Those prints will offer a fresh read on housing and consumption trends. For CRISPR Therap, the calendar is light on company-specific events, so price action is likely to remain driven by sector rotation and the broader gene-editing narrative. Any new clinical readouts or pipeline updates would be the wildcard to watch. ## In Short CRISPR Therap rallied hard this week without a company-specific catalyst, fuelled by sector momentum and a shift in risk appetite. The rating backdrop is broadly supportive—the consensus target sits well above spot—though the wide spread between high and low targets underscores the uncertainty baked into the pipeline story. The latest session’s fund flow split shows large-lot money turning net buyer while retail and mid-tier flows were net sellers, adding a layer of divergence beneath the surface. Whether the rally holds will hinge on the durability of sector momentum and any concrete pipeline progress from the company itself. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md) ## Related News & Research - [Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP](https://longbridge.com/en/news/295199690.md) - [Why Wheaton Precious Metals zoomed 11% higher today](https://longbridge.com/en/news/296415311.md) - [Pixel 11 Pro XL review: Snappier cameras can’t hide an iterative upgrade](https://longbridge.com/en/news/296683565.md) - [11:00 ETLuxor Energy and Bentaus Complete First AI GPU Response to ERCOT 4CP Signals](https://longbridge.com/en/news/296805407.md) - [The Pixel 11 Pro is a great phone, no thanks to its flashiest new features](https://longbridge.com/en/news/296379422.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**